Skip to content

Author

Marleen Kok

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.

BACKGROUND We evaluated pembrolizumab plus chemotherapy versus chemotherapy alone in participants with PD-L1‒positive, hormone receptor-positive (HR+)/HER2- advanced breast cancer after progression on prior endocrine-based therapy (ET). PATIENTS AND METHODS Participants with locally recurrent inoperable or metastatic...

H. Rugo, M. Kok, A. Gonçalves et al. · 0 citations
Open access Sep 2026

A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics.

F fibrovascular and myeloid reprogramming is establish fibrovascular and myeloid reprogramming as a coordinated resistance program, identify actionable therapeutic targets, and support microenvironment stratification in future ICI-based trials.

N. Van Renne, E. Agostinetto, Andrea Joaquín-García et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.